SCYNEXIS, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 51
- Market Cap
- $56M
- Website
- http://www.scynexis.com
Clinical Trials
33
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (32 trials with phase data)• Click on a phase to view related trials
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
- Conditions
- Vulvovaginal CandidiasisCandida InfectionVaginal Candidiasis
- Interventions
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT06954493
- Locations
- 🇺🇸
Woodland Research Northwest (WRN), Rogers, Arkansas, United States
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
- Conditions
- Candida InfectionVaginal CandidiasisVulvovaginal Candidiasis
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05908682
- Locations
- 🇮🇳
AWINSA, New Delhi, Vasant Vihar, India
ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05668429
- Locations
- 🇬🇧
Quotient Sciences Limited, Nottingham, United Kingdom
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05399641
- Locations
- 🇺🇸
Precision Trials, AZ, Phoenix, Arizona, United States
🇺🇸Women's Healthcare Research, San Diego, California, United States
🇺🇸Wake Research (MCCR), San Diego, California, United States
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
- Conditions
- Candidiasis, InvasiveCandidemia
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT05178862
- Locations
- 🇺🇸
University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
🇺🇸Banner University Medical Center-Tucson, Tucson, Arizona, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
NanoNewron Secures $2.5M NIH Grant to Advance Blood-Brain Barrier Crossing TNF-Alpha Inhibitor for Alzheimer's Disease
NanoNewron received a $2.5 million NIH STTR Phase 2 grant to advance its NN-840 program, a TNF-alpha inhibitor designed to cross the blood-brain barrier for Alzheimer's disease treatment.
SCYNEXIS Presents Promising Data on SCY-247 Against Drug-Resistant Fungal Infections at TIMM-12 Congress
SCYNEXIS will present six studies at TIMM-12 demonstrating SCY-247's broad-spectrum antifungal activity against drug-resistant Candida auris, C. glabrata, and Aspergillus species.
Iterum Therapeutics Appoints Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH Launch
Iterum Therapeutics has appointed Christine Coyne as Chief Commercial Officer to lead the upcoming U.S. launch of ORLYNVAH, an FDA-approved oral antibiotic for uncomplicated urinary tract infections.